ReviewNature reviews. Urology2022
Race and prostate cancer: genomic landscape.
Review in Nature reviews. Urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- A systematic review and meta-analysis of the prevalence and risk factors of prostate cancer in Nigeria.BMC cancer · 2025Pooled it
- Epigenetic modulation of prostate cancer disparities in men with African ancestry.Nature reviews. Urology · 2026Review
- Article
- Disparities in Cancer and Cardiovascular Disease Mortality Among Asian Americans Diagnosed with Urologic Cancer.Journal of racial and ethnic health disparities · 2026Article
- The distinct molecular profile of metastatic prostate cancer in the mixed Brazilian population.Genetics in medicine open · 2026Article
- Association between ancestry and tumor somatic mutations in a large national cohort of women with breast cancer.NPJ breast cancer · 2025Article
- Single-Cell and Bulk RNA Sequencing Highlights Intra-Tumoral Heterogeneity and Malignant Progression Mechanisms in Prostate Cancer.Journal of cellular and molecular medicine · 2025Article
- A retrospective analysis of tissue, liquid, and germline testing in Hispanic and non-Hispanic men with advanced hormone-sensitive prostate cancer.Urologic oncology · 2025Article
- Exploration of social determinants of health and prostate cancer prevalence in the US: a cross-sectional study of NHANES data from 2003 to 2010.Frontiers in public health · 2025Article
- Current landscape of exosomal non-coding RNAs in prostate cancer: Modulators and biomarkers.Non-coding RNA research · 2024Review
- Review
- Genetic and biological drivers of prostate cancer disparities in Black men.Nature reviews. Urology · 2024Review
- Evaluation of Survival Outcomes Among Black and White Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis.European urology open science · 2024Article
- Association between patient ethnicity and prostate cancer diagnosis following a prostate-specific antigen test: a cohort study of 730,000 men in primary care in the UK.BMC medicine · 2024Article
- Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Review
- Unique Spectrum of Activating BRAF Alterations in Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Preclinical models of prostate cancer - modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo.Nature reviews. Urology · 2023Review
- Actionable Genomic Alterations in Prostate Cancer Among Black and White United States Veterans.The oncologist · 2023Article
- Article
- Genomic, epigenomic, and transcriptomic signatures of prostate cancer between African American and European American patients.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
Abstract
In the past 20 years, new insights into the genomic pathogenesis of prostate cancer have been provided. Large-scale integrative genomics approaches enabled researchers to characterize the genetic and epigenetic landscape of prostate cancer and to define different molecular subclasses based on the combination of genetic alterations, gene expression patterns and methylation profiles. Several molecular drivers of prostate cancer have been identified, some of which are different in men of different races. However, the extent to which genomics can explain racial disparities in prostate cancer outcomes is unclear. Future collaborative genomic studies overcoming the underrepresentation of non-white patients and other minority populations are essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.